Glycine insulin is generally not recommended to be given as a second injection in the morning and evening, and the specific dosage is as prescribed by the doctor. Glycine insulin is a biosynthetic human insulin analog that utilizes recombinant DNA technology and is commonly available in injectable form for adult patients with type 1 and type 2 diabetes mellitus requiring insulin therapy, adolescents, and children aged 6 years and older with type 1 diabetes mellitus. The drug should be contraindicated in patients with hypoglycemia and in those who are allergic to insulin glargine or any of the excipients in its injections. A common adverse reaction to the use of the drug is hypoglycemic reaction. The drug has a long-acting hypoglycemic effect and it is recommended that it should be injected subcutaneously once a day at a fixed time, usually at bedtime. A second injection in the morning and evening is not recommended. In addition, the drug can be co-administered with short-acting insulin, rapid-acting insulin analogs and oral medications according to the patient’s condition. The specific use of the drug should be under the guidance of a specialist physician, and should not be used without authorization.